Aktis Oncology Inc., a clinical-stage biotechnology company that counts Eli Lilly & Co. among its backers, raised $317.7 million in an initial public offering priced at the top of the marketed range.

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lilly (LLY 3.74%) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in ...

Eli Lilly & Co slashed the price of its blockbuster weight-loss and diabetes drug Mounjaro in China, intensifying competition ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

(Editor’s note: This story was written before Eli Manning was not included in the Pro Football Hall of Fame class of 2025.) Two guys are sitting in a bar. They could be talking about who the Giants’ ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” ...

Eli Lilly stays a Strong Buy as GLP-1 demand drives revenue/EPS beats, margin gains, and pipeline upside. Click here to read ...